Orchestra BioMed Holdings, Inc. OBIO
Set alert
At close · Oct 30
After hours · Oct 30, 5:02 PM ET
- YTD
- +42.41%
- 1 year
- +47.38%
- Open
- 6.07
- Prev close
- 6.09
- Mkt cap
- 355.22M
- Vol
- 232.43K
- Avg vol
- 337.00K
- EPS
- -0.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.85
- High
- 6.08
- Forward P/E
- -2.66
- Beta
- 0.41
- Short ratio
- 12.51
- Inst. own
- 54.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 5.55
- 200-d avg
- 5.90
- 1y target
- 15.60
News
3 days ago globenewswire.com
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB's fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.…
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
1 week ago globenewswire.com
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
1 month ago globenewswire.com
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation…
1 month ago businesswire.com
OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures
TORONTO--(BUSINESS WIRE)--OBIO® companies supported through its Capital Access Advisory Program have now collectively raised over $1 billion in capital.
1 month ago zacks.com
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there…
1 month ago globenewswire.com
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to…
1 month ago globenewswire.com
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in…
1 month ago benzinga.com
This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.
1 month ago benzinga.com
Crude Oil Surges 6%; Macy’s Shares Fall After Q2 Results
U.S. stocks fell Thursday as the Dow dropped 300+ points; Macy’s slid on weak guidance, while oil rose and producer prices accelerated.
1 month ago benzinga.com
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
1 month ago benzinga.com
This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded SFNC, OBIO, and more.
-
1 month ago benzinga.com
BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target
BTIG analyst Marie Thibault upgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Neutral to Buy and announces $10 price target.
2 months ago globenewswire.com
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
2 months ago globenewswire.com
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
2 months ago globenewswire.com
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
-
2 months ago benzinga.com
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10
Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
2 months ago zacks.com
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago.
-
2 months ago benzinga.com
Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 2.7 percent. This is a 24 percent increase over losses of…
3 months ago defenseworld.net
Affinity Asset Advisors LLC Lowers Holdings in Orchestra BioMed Holdings, Inc. $OBIO
Affinity Asset Advisors LLC lessened its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) by 29.7% during the undefined quarter, according to its most recent filing with the…
3 months ago seekingalpha.com
Orchestra BioMed: Nearing The First Of Two Pivotal Readouts
Orchestra BioMed is approaching pivotal trial readouts for AVIM Therapy and Virtue SAB, both with strong success potential. OBIO operates as an innovation and clinical development platform for…
4 months ago globenewswire.com
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
5 months ago globenewswire.com
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
-
5 months ago benzinga.com
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10
B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
5 months ago globenewswire.com
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $10 price target.
-
5 months ago benzinga.com
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $12 to $13.
5 months ago zacks.com
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.49 per share a year ago.
-
5 months ago benzinga.com
Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.41) by 19.51 percent. This is a 32.65 percent increase over losses…
5 months ago globenewswire.com
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
-
5 months ago benzinga.com
Orchestra BioMed Plans To Complete Enrollment In Its BACKBEAT Study Of Atrioventricular Interval Modulation Therapy By End Of Q3; Plans To Submit Primary Endpoint Data With Medtronic In Q2
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with…
5 months ago globenewswire.com
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
-
5 months ago benzinga.com
Orchestra BioMed Receives $15M Payment From Ligand Pharma Under Previously Disclosed Revenue Participation Right Purchase And Sale Agreement
$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty…
-
5 months ago benzinga.com
Orchestra BioMed Receives $20M Investment From Medtronic Under Previously Announced Strategic Financing Agreement
Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") evaluating Atrioventricular Interval…
5 months ago globenewswire.com
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
-
6 months ago benzinga.com
Orchestra BioMed Announces Second FDA Breakthrough Device Designation For AVIM Therapy Specific To Patients With Uncontrolled Hypertension Despite Use Of Medications, Along With An Indication For A Pacemaker
Together, the two BDDs for AVIM Therapy cover indications that encompass both the broader population of patients with uncontrolled hypertension despite medication and increased cardiovascular risk as…
-
7 months ago benzinga.com
Orchestra BioMed Hldgs Q4 EPS $0.26 Beats $(0.39) Estimate, Sales $30.917M Beat $878.600K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.39) by 166.16 percent. This is a 160.47 percent increase over…
-
9 months ago benzinga.com
Orchestra BioMed Anticipates Up To $21M In Cash Proceeds From Haemonetics Regarding Vivasure Acquisition
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing…
9 months ago benzinga.com
Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts
Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts
-
9 months ago benzinga.com
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $12
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $11 to $12.
-
10 months ago benzinga.com
TD Cowen Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15
TD Cowen analyst Joshua Jennings initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy rating and announces Price Target of $15.
-
11 months ago benzinga.com
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
-
11 months ago benzinga.com
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $11
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target from $12 to $11.
-
11 months ago benzinga.com
Orchestra BioMed Hldgs Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $861.000K Beat $757.600K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.21 percent. This is a 2.44 percent increase over losses…
-
1 year ago benzinga.com
Orchestra BioMed Enters $30M Agreement With Terum To Treat Coronary Artery Disease Globally
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with…
-
1 year ago benzinga.com
Orchestra BioMed Announces First Patient Enrollments In Virtue SAB In Treatment Of Coronary ISR Trial
Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
Orchestra Biomed To Present Data Summary Supporting Transformative Potential Of AVIM Therapy In Management Of Hypertensive Heart Disease At Georgia Innovation Summit In Tbilisi
Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic…
-
1 year ago benzinga.com
OBIO Highlights Long-Term Durability Of AVIM Therapy In Major Clinical Publications And HRX 2025 Presentation
Blog Post - OBIO | AVIM therapy: Durability, Reversibility, and Reproducibility of Effect September 22, 2025 September 22, 2025 | Fellow Shareholders: Recent clinical announcements related to our…